Gilead Sciences (NASDAQ: GILD) declined on Friday after Democratic leaders request a briefing by Gilead on Hepatitis C drug pricing ...

This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE